Glenmede Trust Co. NA Purchases 4,145 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Glenmede Trust Co. NA raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 68,605 shares of the biotechnology company’s stock after acquiring an additional 4,145 shares during the quarter. Glenmede Trust Co. NA owned approximately 0.15% of United Therapeutics worth $24,585,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. ClariVest Asset Management LLC grew its position in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth about $30,000. Innealta Capital LLC bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $33,000. USA Financial Formulas acquired a new stake in shares of United Therapeutics in the third quarter valued at about $33,000. Finally, Brooklyn Investment Group acquired a new stake in shares of United Therapeutics in the third quarter valued at about $33,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of analyst reports. LADENBURG THALM/SH SH raised their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Jefferies Financial Group raised their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Bank of America dropped their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the transaction, the chief financial officer now owns 3,210 shares in the company, valued at $1,108,766.10. This trade represents a 70.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 224 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the sale, the director now owns 5,783 shares of the company’s stock, valued at approximately $2,384,215.24. The trade was a 3.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 127,227 shares of company stock worth $47,398,820 in the last quarter. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Up 0.3 %

Shares of NASDAQ UTHR opened at $378.13 on Thursday. The firm has a market cap of $16.88 billion, a P/E ratio of 16.61, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. The business’s 50 day moving average is $366.18 and its 200-day moving average is $333.84. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business earned $5.38 EPS. Analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.